Reuters logo
BRIEF-FDA advisory panel recommends approval of Novo's degludec insulin
November 8, 2012 / 2:10 PM / in 5 years

BRIEF-FDA advisory panel recommends approval of Novo's degludec insulin

Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel votes that cardiovascular outcomes trial of Novo nordisk’s

degludec insulin should be conducted * FDA advisory panel vote is 12-0, that cardiovascular outcomes trial of

degludec insulin should be conducted * FDA advisory panel votes 8-4 to recommend approval of degludec

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below